Cero Therapeutics Reports Positive Safety Data in Phase 1 AML Trial of CER-1236

Reuters01-07

Cero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Safety Data in Phase 1 AML Trial of CER-1236

CERo Therapeutics Holdings Inc. has announced a clinical update from its ongoing Phase 1 CertainT-1 trial, evaluating CER-1236 in patients with acute myeloid leukemia (AML). The company reported that, following the completion of the dose-limiting toxicity observation period for the first cohort, no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or treatment-related adverse events have been observed to date. In one patient with myelodysplastic syndrome progressing to AML, a 61-day platelet transfusion-free interval was noted after CER-1236 treatment, exceeding commonly referenced clinical benchmarks. Additional clinical details and progress were scheduled to be discussed during an analyst call on January 7, 2026. Results from the study have been presented in this update, with further data expected as the trial progresses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621457-en) on January 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601093468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601093468","market":"nz","top_or_hot":-1,"title":"Cero Therapeutics Reports Positive Safety Data in Phase 1 AML Trial of CER-1236","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Safety Data in Phase 1 AML Trial of CER-1236\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CERo Therapeutics Holdings Inc. has announced a clinical update from its ongoing Phase 1 CertainT-1 trial, evaluating CER-1236 in patients with acute myeloid leukemia (AML). The company reported that, following the completion of the dose-limiting toxicity observation period for the first cohort, no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or treatment-related adverse events have been observed to date. In one patient with myelodysplastic syndrome progressing to AML, a 61-day platelet transfusion-free interval was noted after CER-1236 treatment, exceeding commonly referenced clinical benchmarks. Additional clinical details and progress were scheduled to be discussed during an analyst call on January 7, 2026. Results from the study have been presented in this update, with further data expected as the trial progresses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621457-en) on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cero Therapeutics Reports Positive Safety Data in Phase 1 AML Trial of CER-1236</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCero Therapeutics Reports Positive Safety Data in Phase 1 AML Trial of CER-1236\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-07 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Safety Data in Phase 1 AML Trial of CER-1236\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CERo Therapeutics Holdings Inc. has announced a clinical update from its ongoing Phase 1 CertainT-1 trial, evaluating CER-1236 in patients with acute myeloid leukemia (AML). The company reported that, following the completion of the dose-limiting toxicity observation period for the first cohort, no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or treatment-related adverse events have been observed to date. In one patient with myelodysplastic syndrome progressing to AML, a 61-day platelet transfusion-free interval was noted after CER-1236 treatment, exceeding commonly referenced clinical benchmarks. Additional clinical details and progress were scheduled to be discussed during an analyst call on January 7, 2026. Results from the study have been presented in this update, with further data expected as the trial progresses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621457-en) on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL5t1xzn:1","article_id":"2601093468","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601093468","pubTimestamp":1767794950,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CERo Therapeutics Holdings Inc. has announced a clinical update from its ongoing Phase 1 CertainT-1 trial, evaluating CER-1236 in patients with acute myeloid leukemia . The company reported that, following the completion of the dose-limiting toxicity observation period for the first cohort, no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or treatment-related adverse events have been observed to date. In one patient with myelodysplastic syndrome progressing to AML, a 61-day platelet transfusion-free interval was noted after CER-1236 treatment, exceeding commonly referenced clinical benchmarks. Additional clinical details and progress were scheduled to be discussed during an analyst call on January 7, 2026. Results from the study have been presented in this update, with further data expected as the trial progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4112":"金融交易所和数据","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","CERO":"CERo Therapeutics Holdings, Inc.","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD"},"translate_title":"Cero Therapeutics报告CER-1236 1期AML试验的积极安全性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CERO":0.9},"content_text":"Cero Therapeutics Reports Positive Safety Data in Phase 1 AML Trial of CER-1236\n    \n\n        CERo Therapeutics Holdings Inc. has announced a clinical update from its ongoing Phase 1 CertainT-1 trial, evaluating CER-1236 in patients with acute myeloid leukemia (AML). The company reported that, following the completion of the dose-limiting toxicity observation period for the first cohort, no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or treatment-related adverse events have been observed to date. In one patient with myelodysplastic syndrome progressing to AML, a 61-day platelet transfusion-free interval was noted after CER-1236 treatment, exceeding commonly referenced clinical benchmarks. Additional clinical details and progress were scheduled to be discussed during an analyst call on January 7, 2026. Results from the study have been presented in this update, with further data expected as the trial progresses.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621457-en) on January 07, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601093468","isCrawlerRequest":true}